Anti-ROR2 Rabbit Monoclonal Antibody

Overview

This product is an anti-ROR2 antibody for target detection and characterization. Key identifiers include host species: Rabbit; Monoclonal; clone 23R31; isotype IgG; reactivity: Human. Reported application contexts include WB, ICC, IF, Flow (as provided in the source record). Boster Bio Anti-ROR2 Rabbit Monoclonal Antibody catalog # M01840-1. Tested in WB, ICC/IF, Flow Cytometry applications. This antibody reacts with Human.

Key elements and design rationale

• Target: ROR2 (Transcription factor jun-B).
• Antibody format: Monoclonal; clone 23R31; isotype IgG.
• Host: Rabbit.
• Species reactivity: Human (confirm in your model system with appropriate controls).

This description is intended to help interpret the antibody design and the biological context of the target using the fields provided in the catalog record, alongside general experimental considerations.

Biological background

ROR2 (protein: Lysosome-associated membrane glycoprotein 2 (Lamp2)) is a commonly studied target in molecular and cellular biology. Functional context (as provided): Transcription factor involved in regulating gene activity following the primary growth factor response. Binds to the DNA sequence 5'-TGA[CG]TCA-3'. Reported cellular localization context: Nucleus. Tissue expression notes (as provided): Expressed in various tumor cell lines. In insulinoma tissue predominantly expressed in precancerous lesions. .

Research relevance and current trends

• Research context keywords from the source record include: Cancer Susceptibility,Domain Families,Epigenetics and Nuclear Signaling,Hlh/Leucine Zipper,Proto-Oncogenes,Transcription.
• Current studies often focus on connecting target abundance/localization to pathway perturbations across models, tissues, and cell states.
• Quantitative and multiplexed assays (e.g., imaging + immunoblot panels) are commonly used to compare phenotypes across conditions and time-courses.

Common research applications

• Western blotting (WB): assess relative target abundance across samples, treatments, or time-points.
• Immunofluorescence/ICC (IF/ICC): visualize subcellular localization patterns and cell-to-cell heterogeneity.
• Flow cytometry: quantify target-positive populations and compare shifts in marker distributions.

Workflow ideas (metafield): Validate ROR2 antibody specificity using KO/KD control samples (WB/IF/IHC as appropriate), Detect ROR2 expression by Western blot in cell or tissue lysates, Localize ROR2 by immunofluorescence/immunocytochemistry in cultured cells, Quantify ROR2-positive cells by flow cytometry in single-cell suspensions

Notes for experimental interpretation

• Consider isoforms and post-translational modifications (PTMs) that may shift apparent molecular weight or epitope accessibility.
• Apparent molecular weight may vary by sample type and processing (observed MW: 100 kDa; calculated MW: 105 kDa).
• Control concepts: include appropriate negative controls (e.g., isotype, KO/KD samples) and orthogonal validation when feasible.

Additional product details (from the source record)

• Molecular weight (observed): 100 kDa
• Cellular localization (provided): Nucleus.
• Tissue details (provided): Expressed in various tumor cell lines. In insulinoma tissue predominantly expressed in precancerous lesions. .

Customization & Add-ons: Can’t find the antibody you need—or require a custom format for your assay? We can help you source the best match or support custom antibody solutions for diverse research needs, including species and isotype selection, conjugations and labeling (e.g., HRP/AP, biotin, fluorophores), purification grade options (Protein A/G, affinity purified), formulation preferences (buffer selection, carrier-free, glycerol-free), custom concentrations and aliquoting, low-endotoxin options for cell-based work, and application-focused QC/validation support (project dependent). Click Talk to a Scientist to submit a request, email us at support@biohippo.com, or explore our Research Services for additional support—our team will follow up with feasibility details and next steps.